Vericel (VCEL) Interest Expenses (2010 - 2026)
Vericel (VCEL) posted Interest Expenses of $625000.0 for Q2 2026, little changed sequentially from $625000.0 in Q1 2026, and little changed YoY from $625000.0 in Q2 2025.
Vericel (VCEL) Interest Expenses (2010 - 2026) Analysis & Trends
Vericel has reported Interest Expenses for 17 years, with the latest figure at $625000.0 in Q2 2026.
- Quarterly Interest Expenses changed 0.0% year-over-year to $625000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $625000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $41.2 million, down 70.01% from the prior year.
- Interest Expenses was little changed at $625000.0 in Q2 2026 per VCEL's latest filing, from $625000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $159.5 million in Q2 2023 and troughed at $18000.0 in Q1 2022.
- A 5-year average of $18.1 million and a median of $625000.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses soared 797625.0% in 2023, then plunged 99.61% in 2024.
- Over 5 years, Interest Expenses stood at $223000.0 in 2022, then tumbled by 30.04% to $156000.0 in 2023, then surged by 438.46% to $840000.0 in 2024, then advanced by 22.86% to $1.0 million in 2025, then sank by 39.44% to $625000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $625000.0, $625000.0, and $1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 625,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 625,000.00 |
| Mar 31, 2026 | 625,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 625,000.00 |
| Sep 30, 2025 | 625,000.00 |
| Jun 30, 2025 | 625,000.00 |
| Jun 30, 2025 | 625,000.00 |
| Mar 31, 2025 | 625,000.00 |
| Mar 31, 2025 | 625,000.00 |
| Dec 31, 2024 | -61,000.00 |
| Dec 31, 2024 | -61,000.00 |
| Sep 30, 2024 | 625,000.00 |
| Sep 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 625,000.00 |
| Mar 31, 2024 | 625,000.00 |